Table 1 Expression level of PD-L1 in thymic epithelial tumors
From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
No | Ref | TM/TC No | Antibody of PD-L1 | Criteria of Positivity Judgement | Positivity rate |
|---|---|---|---|---|---|
1 | Katsuya et al. [47] | 101/38 | Clone E1L3N | Intensity of staining score (0–3) score 3 | TM:23.0% TC: 70.0% |
2 | Padda et al. [48] | 65/4 | Clone15 | Intensity of staining score (0–3) score 3 | TM:68.0% TC: 75.0% |
3 | Marchevsky et al. [49] | 38/8 | SP142 (1:250) | Membranous expression ≥ 6% | TM:92.0% TC: 50.0% |
4 | Enkner et al. [50] | 37/35 | E1L3N | Staining H-score (cutoff value not defined) | TM:89.0% TC: 53.0% |
5 | Katsuya et al. [51] | 12/18 | E1L3N (1:800) | Intensity of staining score (0–3) score ≥ 1 | TM:67.0% TC:41.0% |
6 | Yokoyama et al. [52] | 82/0 | EPR1161 (1:200) | Cutoff point of the PD-L1–positive rate was calculated to be 38% by Youden’s index | TM:53.7% TC: NA |
7 | Arbour et al. [36] | 12/11 | E1L3N | Membranous expression > 25% | TM: 92.0% TC: 36.0% |
8 | Tiseo et al. [53] | 87/20 | E1L3N (1:500) | Intensity of staining score (0–3) score 3 | TM: 18.0% TC: 65.0% |
9 | Weissferdt et al. [35] | 74/26 | EPR4877 (1:250) | Membranous staining > 5% | TM: 64.0% TC: 54.0% |
10 | Suster et al. [37] | 0/21 | Clone SP142 | Membranous staining > 50% | TM: NA TC: 71.4% |
11 | Owen et al. [54] | 32/3 | 22C3 | Intensity of staining (score 0–5) score 1 | TM: 81.0% TC: 100% |
12 | Hakiri et al. [55] | 81/0 | SP142 (1:50) | Membranous expression ≥ 1% | TM: 27.0% TC: NA |
13 | Guleria et al. [56] | 84/0 | SP263 | Membranous expression > 25% | TM: 82.0% TC: NA |
14 | Duan et al. [45] | 20/13 | Ab58810 (1:200) | Intensity of staining score (1–3). Median value of all scores as the cutoff value | TM: 65.0% TC: 46.2% |
15 | Chen et al. [57] | 40/30 | SP142 | Membranous expression ≥ 5% | TM: 37.5% TC: 76.7% |
16 | Bagir et al. [58] | 38/6 | AM26531AF-N | Membranous staining > 5% | TM: 81.6% TC: 83.3% |
17 | Funaki et al. [46] | 0/43 | SP142(1:100) | Membranous staining > 50% | TM: NA TC: 60.5% |
18 | Wei et al. [44] | 100/69 | Clone E1L3N (1:100) | Membranous staining > 50% | TM:36% TC:37% |
18 | Higuchi et al. [38] | 31/8 | 28–8 | Membranous expression ≥ 1% | TM:51.6% TC:62.5% |
19 | Rouquette et al. [59] | 53/50 | Clone E1L3N Clone 22C3 Clone SP142 Clone SP263 | Membranous staining > 1% | TM: > 92% to 98% TC: 66% to 73% |
20 | Ishihara et al. [60] | 55/11 | Clone SP263 | Membranous staining > 25% | TM: 92.7% TC: 72.7% |
21 | Berardi et al. [10] | 63/5 | DAKO PD-L1 IHC 28–8 PharmDx kit | Membranous staining > 1% | Overall: 25% |
22 | Ishihara et al. [60] | 66 | Clone SP263 Clone AE1/AE3 | The ratio of the PD-L1 positive rate to the AE1/AE3-positive rate | Overall: 38% |